Anti-LCG monoclonal antibody - eXegenics

Drug Profile

Anti-LCG monoclonal antibody - eXegenics

Alternative Names: LCG monoclonal antibody - eXegenics; Lung cancer gene - monoclonal antibody

Latest Information Update: 25 Aug 2003

Price : $50

At a glance

  • Originator eXegenics
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Lung cancer

Most Recent Events

  • 25 Aug 2003 Discontinued - Phase-I for Lung cancer in USA (unspecified route)
  • 01 Aug 2003 Suspended - Phase-I for Lung cancer in USA (unspecified route)
  • 09 Nov 2001 Cytoclonal Pharmaceutics is now called eXegenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top